



12th November 2024

The Secretary,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 544250

The Secretary,
The National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza
Bandra-Kurla Complex
Bandra East, Mumbai - 400 050
Symbol: SANOFICONR

Sub: Outcome of the Board Meeting held on Tuesday, 12th November 2024

Dear Sir/Ma'am,

We refer to our letter dated 5th November 2024 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Tuesday, 12th November 2024, *inter-alia* considered and approved the Unaudited Financial Results for the quarter and nine months ended 30th September 2024.

Further, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we also enclose herewith a copy of the Unaudited Financial Results for the quarter and nine months ended 30th September 2024 approved at this Meeting with a copy of the Limited Review Report duly signed by the Statutory Auditors of the Company.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid Financial Results will also be available on the Company's website on [Financial results - Sanofi India](#)

The meeting of Board of Directors commenced at 12:30 p.m. and concluded at 4:20 p.m.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Sanofi Consumer Healthcare India Limited**

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: FCS 7048

Review Report

To,
The Board of Directors
Sanofi Consumer Healthcare India Limited
Sanofi House,
CTS No. 117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai – 400 072.

1. We have reviewed the accompanying Statement of unaudited financial results of **Sanofi Consumer Healthcare India Limited** (“the Company”), for the quarter and nine months ended September 30, 2024 (“the Statement”), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”), which has been digitally signed by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management has been reviewed by the Audit Committee in their meeting held on November 11, 2024 and approved by the Company’s Board of Directors at their meeting held on November 12, 2024, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Other Matter

In accordance with the Scheme of Arrangement between Sanofi India Limited (“SIL”) and its shareholders and creditors and Sanofi Consumer Healthcare India Limited (“SCHIL”) as (“the Scheme”) approved by the Hon'ble National Company Law Tribunal, Mumbai Bench by an order dated May 07, 2024, the Consumer Healthcare business, along with its related assets and liabilities at the values appearing in the books of accounts of SIL on the close of business hours as on May 10, 2023 (Incorporation Date), was demerged, transferred and vested into the Company with effect from May 10, 2023 as set out in Appendix C of Ind AS 103 ‘Business Combinations’. The appointed date and effective date of the Scheme was June 01, 2023, and June 01, 2024, respectively, however, financials are drawn from May 10, 2023, as per the requirement of Ind AS 103. Business was run by SIL in trust for SCHIL and risk associated with the business remains with SCHIL from date of business transfer. Accordingly, previous year quarter results and results for the nine months ended September 30, 2023 are from May 10, 2023, to September 30, 2023, and not comparable with current year quarter and the nine-month results.

Accordingly, the figures for quarter and nine months ended September 30, 2023, and the previous year ended December 31, 2023, have been accounted by the management in respect of Consumer Healthcare Business after considering the adjustments to give effect of the Scheme.

With respect to the above, we have reviewed the adjustments which have been reported in the Statement.

Our conclusion is not modified in respect of this matter.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS**

Firm Registration No. 104607W / W100166

Damarla Sai

Venkata Ramana

Digitally signed by Damarla Sai Venkata Ramana
DN: cn=R, o=Personal, ou=0721,
email=sai@damarlasai.com, c=IN,
2.5.4.20=9599178562514973266015188fabcf59461b09d
e741bb740d994ac652a1063, postalCode=421301,
st=Maharashtra
serialNumber=d083110d4f1d0b64abb985e5d0c4ced3e1d
177148cc0f5c0d319446070121a, cn=Damarla Sai
Venkata Ramana
Date: 2024.11.12 15:38:52 +05'30'

**Sai Venkata Ramana Damarla
Partner**

Membership. No. 107017

UDIN: 24107017BKERXX4957

Place: Mumbai

Date: November 12, 2024

Sanofi Consumer Healthcare India Limited

Registered Office : 3rd Floor, Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.

Corporate Identity Number: U21002MH2023PLC402652

Tel no: (91-22) 28032000 Fax No: (91-22) 28032846

Website: www.sanofi.in Email: igrc.schil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2024

Particulars	₹ in Million					
	Quarter ended 30.09.2024 (Unaudited) Refer note: 3	Quarter ended 30.06.2024 (Unaudited) Refer note: 3	Quarter ended 30.09.2023 (Unaudited) Refer note: 3	Nine Months ended 30.09.2024 (Unaudited) Refer note: 3	Nine Months ended 30.09.2023 (Unaudited) wef 10.05.23 - 30.09.2023 Refer note: 3	Year ended 31.12.2023 (Unaudited) wef 10.05.23 - 31.12.2023 Refer note: 3
1. Revenue from Operations	1,599	1,644	2,103	5,355	3,106	5,254
2. Other Income	42	8	13	80	15	41
3. Total Income (1+2)	1,641	1,652	2,116	5,435	3,121	5,295
4. Expenses						
(a) Cost of Materials Consumed	141	317	504	1,126	812	1,364
(b) Purchases of stock in trade	144	-	80	237	132	200
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	102	138	23	79	(34)	(45)
(d) Employee benefits expense	274	248	217	751	350	544
(e) Finance costs	34	1	-	35	-	-
(f) Depreciation and amortisation expense	15	11	7	35	11	20
(g) Other expenses	307	305	333	1,077	553	1,002
Total Expenses	1,017	1,020	1,164	3,340	1,824	3,085
5. Profit before exceptional items and tax (3-4)	624	632	952	2,095	1,297	2,210
6. Exceptional items (Refer notes 6 & 7)	(12)	(243)	-	(255)	-	(18)
7. Profit before tax (5+6)	612	389	952	1,840	1,297	2,192
8. Tax expense						
Current Tax	169	129	242	520	329	563
Deferred Tax	(7)	(30)	(2)	(47)	(2)	(19)
9. Profit for the period /year (7-8)	450	290	712	1,367	970	1,648
10. Other comprehensive income (OCI) (Net of Tax)	-	-	-	-	-	-
11. Total comprehensive income for the period/year (9+10)	450	290	712	1,367	970	1,648
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230	230
13. Other equity	-	-	-	-	-	1,846
14. Basic and diluted earnings per share (not annualised) (in ₹)	19.54	12.58	30.92	59.36	42.12	71.54

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated November 12, 2024

Digitally signed by Damarla Sai Venkata Ramana
 DN: c=IN, o=Personal, title=0721, pseudonym=133317923944578480x29PPDz5 891SV,
 2.5.4.20=956901f85b6251d9702e60151bfab cf39d61b09de741bb740d93acfd2a1063, postalCode=421301, st=Maharashtra, serialNumber=5085310dd1d09c6abb998Se6 d0c4ced3e8d17f71e8cccf5c0dd19446b9b12 1a, cn=Damarla Sai Venkata Ramana
 Date: 2024.11.12 15:55:34 +05'30'

Digitally signed by Himanshu Bakshi
 Date: 2024.11.12 15:50:10 +05'30'

Notes:

1. These unaudited financial results have been prepared in accordance with recognition and measurement principles of the Indian Accounting Standards ("Ind AS"), as prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
2. The statutory auditors have issued limited review report with unmodified conclusion on the above unaudited financial results for the quarter and nine months ended September 30, 2024. The unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025 have been reviewed by the Audit Committee in their meeting held on November 11, 2024, and approved by the Board of Directors of the Company at its meeting held on November 12, 2024
3. The Board of Sanofi India Limited (SIL) on May 10, 2023, had approved a Scheme of arrangement under Sections 230 to 232 of the Companies Act, 2013 ("Scheme"), to demerge the Consumer Healthcare business of the Company into its wholly owned subsidiary Sanofi Consumer Healthcare India Limited ("SCHIL"). In accordance with the Scheme of Arrangement between Sanofi India Limited and its shareholders and creditors and SCHIL as ("the Scheme") approved by the Hon'ble National Company Law Tribunal, Mumbai Bench by an order dated May 7, 2024, the Consumer Healthcare business, along with its related assets and liabilities at the values appearing in the books of accounts of SIL on the close of business hours as on May 10, 2023 (Incorporation Date), was demerged, transferred and vested into the Company with effect from May 10, 2023 as set out in Appendix C of Ind AS 103 'Business Combinations'. The appointed date and effective date of the Scheme was June 1, 2023 and June 1, 2024 respectively, however, financials are drawn from May 10, 2023 as per the requirement of Ind AS 103. Business was run by SIL in trust for SCHIL and risk associated with the business remains with SCHIL from date of business transfer. Accordingly, the previous year quarter results and results for the nine months ended September 2023 are from May 10, 2023, to September 30, 2023, and not comparable with current year quarter and the nine month results.

Results of the quarter ended September 30, 2024, are not comparable with results of quarter ended June 30, 2024 due to the seasonality of business, voluntary product recall and pending authorization from the receiving markets.

4. Pursuant to the demerger, the Company has recognized in its books of account, the carrying amount of assets and liabilities as on May 31, 2024, amounting to ₹ 3,648 million and ₹ 1,764 million respectively, pertaining to the Consumer Healthcare business transferred from SIL. The consideration received over the carrying amount of net assets transferred along with the profits earned during the period May 10, 2023, to May 31, 2024, aggregating to ₹1,884 million (including Capital Reserve of ₹407 million) and net of dividend paid by SIL in trust on behalf of the Company amounting to ₹ 1,152 million, has been credited to Reserves in accordance with the Scheme as on May 31, 2024.
5. The record date, for determining the eligibility of the shareholders of SIL for allotting shares of the SCHIL in the ratio of 1 (One) fully paid-up new equity share of ₹.10 each of the Company for every 1 (One) equity share of ₹.10 each of SIL (pursuant to the Scheme of Arrangement) was fixed as June 13, 2024. Accordingly, the Company has allotted 23,030,622 shares amounting to ₹ 230 million (adjusted against Capital Reserve) to the eligible shareholders of SIL on June 25, 2024.
6. Company had voluntarily decided to recall Allegra Suspension and Combiflam Suspension as precautionary measure from distributors, hospitals, and retailers on July 19,2024. Earlier, Company recalled Depura Adult and Depura Kids produced by the same manufacturer. The recall of the products is substantially completed from distributors and retailers and expected to receive small returns from retailers before the year end. The Company has taken a decision to temporarily suspend manufacturing of aforesaid products to review and streamline the manufacturing and quality processes at the third-party manufacturer engaged in manufacturing. Quality is paramount to the company and endeavor is to bring back the products to the market as soon as possible. Our non-recalled portfolio continues to perform strongly in the market.
7. Exceptional item for the nine months ended September 30, 2024, is Rs. 255 million which includes product recall related cost towards Sales return and inventory write off Rs.108 million (previous year ended December 31, 2023: Nil), expenses towards issuance of shares and listing formalities amounting to Rs.77 million (previous year ended December 31, 2023: Rs.18 million) and demerger expenses amounting to Rs.70 million (previous year ended December 31, 2023: Nil).
8. The Company has a single business segment namely 'Pharmaceutical Business.

9. The Company listed its equity shares with the National Stock Exchange of India Limited (“NSE”) and the BSE Limited (“BSE”) on September 13, 2024.
10. There is a change of Holding Company from ‘Hoechst GmbH and Sanofi S.A. to ‘Opella Healthcare Participations BV’ in October 2024. However, Sanofi S.A remains the ultimate Holding Company.
11. The Company does not have any subsidiary, associates or joint ventures as on September 30, 2024.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated November 12, 2024

**Damarla Sai
Venkata
Ramana**

Digitally signed by Damarla Sai Venkata Ramana
DN: cn=IN, o=Personal, title=0721,
pseudonym=133317923944578480x29PPDz15b9
15V,
2.5.4.20=956901f85b6251d9702e60151b8fabcf3
9d61b09de741bb740d934acfd2a1063,
postalCode=421301, st=Maharashtra,
serialNumber=6085310dd1d0b64abb985e6d0
c4ced3e8d17771e8ccce5cd0d19446b9b121a,
cn=Damarla Sai Venkata Ramana
Date: 2024.11.12 15:56:04 +05'30'

November 12, 2024

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

**Himanshu
Bakshi**

Himanshu Bakshi
Managing Director
DIN: 08188412

Digitally signed by
Himanshu Bakshi
Date: 2024.11.12 15:50:39
+05'30'